Found: 31
Select item for more details and to access through your institution.
Glycaemic control and sepsis risk in adults with type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1942, doi. 10.1111/dom.15060
- By:
- Publication type:
- Article
Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1794, doi. 10.1111/dom.15051
- By:
- Publication type:
- Article
A UK nationwide study of adults admitted to hospital with diabetic ketoacidosis or hyperosmolar hyperglycaemic state and COVID‐19.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2012, doi. 10.1111/dom.15076
- By:
- Publication type:
- Article
iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2005, doi. 10.1111/dom.15074
- By:
- Publication type:
- Article
Assessment of circulating insulin using liquid chromatography‐mass spectrometry during insulin glargine treatment in type 2 diabetes: Implications for estimating insulin sensitivity and β‐cell function.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1995, doi. 10.1111/dom.15072
- By:
- Publication type:
- Article
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1985, doi. 10.1111/dom.15070
- By:
- Publication type:
- Article
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2043, doi. 10.1111/dom.15065
- By:
- Publication type:
- Article
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1973, doi. 10.1111/dom.15064
- By:
- Publication type:
- Article
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1964, doi. 10.1111/dom.15063
- By:
- Publication type:
- Article
Clinical features of generalized lipodystrophy in Turkey: A cohort analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1950, doi. 10.1111/dom.15061
- By:
- Publication type:
- Article
Diabetes, Obesity and Metabolism.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1783, doi. 10.1111/dom.14754
- Publication type:
- Article
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1932, doi. 10.1111/dom.15058
- By:
- Publication type:
- Article
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2038, doi. 10.1111/dom.15057
- By:
- Publication type:
- Article
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1922, doi. 10.1111/dom.15056
- By:
- Publication type:
- Article
Advanced hybrid closed loop system use in elderly with type 1 diabetes: Effectiveness and safety in a prospective, observational, 1‐year follow‐up real‐world study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2034, doi. 10.1111/dom.15055
- By:
- Publication type:
- Article
High cereal fibre but not total fibre is associated with a lower risk of type 2 diabetes: Evidence from the Melbourne Collaborative Cohort Study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1911, doi. 10.1111/dom.15054
- By:
- Publication type:
- Article
Association between walking pace and incident type 2 diabetes by adiposity level: A prospective cohort study from the UK Biobank.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1900, doi. 10.1111/dom.15053
- By:
- Publication type:
- Article
Antidiabetes medication initiation trends in US adults with cirrhosis and type 2 diabetes: A nationwide study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2028, doi. 10.1111/dom.15052
- By:
- Publication type:
- Article
HbA1c trajectories over 3 years in people with type 2 diabetes starting second‐line glucose‐lowering therapy: The prospective global DISCOVER study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1890, doi. 10.1111/dom.15050
- By:
- Publication type:
- Article
Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1874, doi. 10.1111/dom.15047
- By:
- Publication type:
- Article
Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion assessed using continuous glucose monitoring: A prospective observational study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1883, doi. 10.1111/dom.15049
- By:
- Publication type:
- Article
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
- By:
- Publication type:
- Article
Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1855, doi. 10.1111/dom.15045
- By:
- Publication type:
- Article
Ketone monoester increases circulating levels of LEAP2 and decreases appetite in healthy men.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 2023, doi. 10.1111/dom.15044
- By:
- Publication type:
- Article
Effect of gastric distension with concurrent small intestinal saline or glucose infusion on incretin hormone secretion in healthy individuals: A randomized, controlled, crossover study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1849, doi. 10.1111/dom.15042
- By:
- Publication type:
- Article
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1839, doi. 10.1111/dom.15041
- By:
- Publication type:
- Article
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1830, doi. 10.1111/dom.15040
- By:
- Publication type:
- Article
Identification of predictive factors of diabetic ketoacidosis in type 1 diabetes using a subgroup discovery algorithm.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1823, doi. 10.1111/dom.15039
- By:
- Publication type:
- Article
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1813, doi. 10.1111/dom.15038
- By:
- Publication type:
- Article
Allometric body shape indices, type 2 diabetes and kidney function: A two‐sample Mendelian randomization study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1803, doi. 10.1111/dom.15037
- By:
- Publication type:
- Article
COVID‐19 associated ketosis and diabetic ketoacidosis: A rapid review.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1785, doi. 10.1111/dom.15036
- By:
- Publication type:
- Article